Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H5MS
|
||||
| Former ID |
DIB000199
|
||||
| Drug Name |
CT84.66
|
||||
| Synonyms |
T84.66; Anti-CEA IgG1 radioimmunotherapeutic, City of Hope; Anti-carcinoembryonic antigen IgG1 radioimmunotherapeutic, City ofHope
|
||||
| Indication | Breast cancer [ICD9: 174, 175; ICD10:C50] | Phase 1/2 | [522271] | ||
| Company |
City of Hope
|
||||
| Target and Pathway | |||||
| Target(s) | Carcinoembryonic antigen-related cell adhesion molecule 5 | Target Info | [526990] | ||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| References | |||||
| Ref 522271 | ClinicalTrials.gov (NCT00645710) Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.